Daily close, T-120 (4/17/25) through T+5. Run-up high $136.9 on 10/1/25, low $97.78 on 5/15/25 (T-120 to T-1). FDA decision 10/2/25. Historical price action, not a forecast.
Positioning before the decision
On Sep 18, 2025, 14 days before the decision date, at-the-money options priced a move of ±7.9% through Oct 17, 2025 (the first listed expiry after the decision; ATM implied volatility 35%). The stock closed +0.2% at the first close across the decision and +0.6% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Decision facts
FDA decision date2025-10-02
DrugZepzelca (lurbinectedin) and Atezolizumab (Tecentriq)
IndicationFirst-line, Small Cell Lung Cancer (SCLC)
Was Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) approved by the FDA?
Yes. The FDA approved the application for Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) on October 2, 2025. The primary source is linked on this page.
What was Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) under FDA review for?
The application covered First-line, Small Cell Lung Cancer (SCLC). The FDA approved the application on October 2, 2025.
How did JAZZ stock react to the FDA decision?
On the decision day JAZZ moved +0.2%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.